If you look at Bell's valuation and remove the probability ratios (assuming P3 success and FDA approval) they have Neuren valued at $800m on Trofinetide for Retts and Fragile X alone. Success of the Trofinetide molecule then adds weight to the potential of NNZ-2591 the value of which needs to be added to the $800m plus the multitude of other potential applications for either drug.
I my view if it isn't $1B minimum then we haven't achieved full value and the board should continue down the P3 path until we do. I would be disappointed if the sold out early for less than this. I think the shareholders have shown they are in for the long haul and we should run the course to unlock full potential.
Neuren - Cracking the $200m m/cap again., page-47
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1060 | $19.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.87 | 209 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |